HK1258249A1 - 用於測定icos表達的基因標誌 - Google Patents
用於測定icos表達的基因標誌Info
- Publication number
- HK1258249A1 HK1258249A1 HK19100610.9A HK19100610A HK1258249A1 HK 1258249 A1 HK1258249 A1 HK 1258249A1 HK 19100610 A HK19100610 A HK 19100610A HK 1258249 A1 HK1258249 A1 HK 1258249A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- gene signatures
- icos expression
- determining
- determining icos
- expression
- Prior art date
Links
- 230000004547 gene signature Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562245180P | 2015-10-22 | 2015-10-22 | |
| US201662311486P | 2016-03-22 | 2016-03-22 | |
| US201662359069P | 2016-07-06 | 2016-07-06 | |
| US201662395970P | 2016-09-16 | 2016-09-16 | |
| PCT/US2016/058032 WO2017070423A1 (en) | 2015-10-22 | 2016-10-21 | Gene signatures for determining icos expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1258249A1 true HK1258249A1 (zh) | 2019-11-08 |
Family
ID=57249880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK19100610.9A HK1258249A1 (zh) | 2015-10-22 | 2019-01-14 | 用於測定icos表達的基因標誌 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10968277B2 (zh) |
| EP (1) | EP3365372A1 (zh) |
| JP (1) | JP2018534927A (zh) |
| KR (1) | KR20180066236A (zh) |
| CN (1) | CN108350505A (zh) |
| AU (1) | AU2016342269A1 (zh) |
| CA (1) | CA2998208A1 (zh) |
| HK (1) | HK1258249A1 (zh) |
| IL (1) | IL258155A (zh) |
| TW (1) | TW201723190A (zh) |
| WO (1) | WO2017070423A1 (zh) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| CN114907481A (zh) * | 2015-03-23 | 2022-08-16 | 震动疗法股份有限公司 | Icos的抗体 |
| EP3365372A1 (en) | 2015-10-22 | 2018-08-29 | Jounce Therapeutics, Inc. | Gene signatures for determining icos expression |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| CN109689688B (zh) | 2016-08-09 | 2023-06-13 | 科马布有限公司 | 抗icos抗体 |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| WO2018187191A1 (en) * | 2017-04-03 | 2018-10-11 | Jounce Therapeutics, Inc | Compositions and methods for the treatment of cancer |
| TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| WO2019122882A1 (en) | 2017-12-19 | 2019-06-27 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| IT201800001315A1 (it) * | 2018-01-18 | 2019-07-18 | Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro | Nuovi agenti terapeutici antitumorali |
| WO2019222188A1 (en) | 2018-05-14 | 2019-11-21 | Jounce Therapeutics, Inc. | Methods of treating cancer |
| WO2020081905A1 (en) | 2018-10-18 | 2020-04-23 | Jounce Therapeutics, Inc | Methods for treating cancer |
| WO2020086802A1 (en) | 2018-10-24 | 2020-04-30 | Jounce Therapeutics, Inc. | Methods and compositions for the treatment of cancer and infectious diseases |
| US20210355222A1 (en) | 2018-10-26 | 2021-11-18 | Jounce Therapeutics, Inc. | Methods of Treating Cancer |
| WO2020185739A1 (en) | 2019-03-11 | 2020-09-17 | Jounce Therapeutics, Inc. | Anti-icos antibodies for the treatment of cancer |
| US20220378909A1 (en) | 2019-11-05 | 2022-12-01 | Jounce Therapeutics, Inc. | Methods of Treating Cancer with Anti-PD-1 Antibodies |
| WO2021146303A1 (en) | 2020-01-13 | 2021-07-22 | Jounce Therapeutics, Inc. | Methods for the treatment of cancer |
| IL297313A (en) | 2020-04-20 | 2022-12-01 | Jounce Therapeutics Inc | Compositions and methods for vaccination and treatment of infectious diseases |
| GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
| US20220396623A1 (en) | 2021-05-18 | 2022-12-15 | Kymab Limited | Uses of anti-icos antibodies |
| WO2023222854A1 (en) | 2022-05-18 | 2023-11-23 | Kymab Limited | Uses of anti-icos antibodies |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| EP0564531B1 (en) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| CA2293829C (en) | 1997-06-24 | 2011-06-14 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
| US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| CA2305350C (en) | 1997-09-23 | 2015-04-07 | Bundesrepublik Deutschland Letztvertreten Durch Den Direktor Des Robert-Koch-Instituts | Costimulating polypeptide of t cells, monoclonal antibodies, and the preparation and use thereof |
| DE19821060A1 (de) | 1997-09-23 | 1999-04-15 | Bundesrepublik Deutschland Let | Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung |
| AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| BR9813365A (pt) | 1997-12-05 | 2004-06-15 | Scripps Research Inst | Método para produção e humanização de um anticorpo monoclonal de rato |
| DK1068241T3 (da) | 1998-04-02 | 2008-02-04 | Genentech Inc | Antistofvarianter og fragmenter deraf |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| EP1137436B1 (en) | 1998-12-03 | 2008-06-04 | The Regents Of The University Of California | Stimulation of T-cells against self antigens using CTLA-4 blocking agents |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| NZ551331A (en) | 1999-02-03 | 2008-08-29 | Amgen Inc | Methods using polypeptides involved in immune response |
| PT1914244E (pt) | 1999-04-09 | 2013-07-26 | Kyowa Hakko Kirin Co Ltd | Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico |
| PT1210428E (pt) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, um recetor para b7-4 e suas utilizações |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| ATE366814T1 (de) | 1999-09-21 | 2007-08-15 | Genetics Inst Llc | Gl50 moleküle, sowie verwendungen derselben |
| JP4668498B2 (ja) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | ポリペプチドの製造方法 |
| CA2393869A1 (en) | 1999-12-15 | 2001-06-21 | Genetech,Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
| WO2001075166A2 (en) | 2000-03-31 | 2001-10-11 | Genentech, Inc. | Compositions and methods for detecting and quantifying gene expression |
| CA2414331C (en) | 2000-06-28 | 2011-11-29 | Genetics Institute, Llc. | Pd-l2 molecules: novel pd-1 ligands and uses therefor |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| CA2785941C (en) | 2000-10-06 | 2017-01-10 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| ATE378403T1 (de) | 2000-11-30 | 2007-11-15 | Medarex Inc | Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern |
| US20030124149A1 (en) | 2001-07-06 | 2003-07-03 | Shalaby Shalaby W. | Bioactive absorbable microparticles as therapeutic vaccines |
| CN1555411A (zh) | 2001-08-03 | 2004-12-15 | ���迨�����＼���ɷݹ�˾ | 抗体-依赖性细胞毒性增大的抗体糖基化变体 |
| EP1443961B1 (en) | 2001-10-25 | 2009-05-06 | Genentech, Inc. | Glycoprotein compositions |
| EP1441758A2 (de) | 2001-11-09 | 2004-08-04 | MediGene Aktiengesellschaft | Allogene vakzine enthaltend eine ein costimulatorisches polypeptid exprimierende tumorzelle |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| EP1498490A4 (en) | 2002-04-09 | 2006-11-29 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING ANTIBODY COMPOSITION |
| JP4628679B2 (ja) | 2002-04-09 | 2011-02-09 | 協和発酵キリン株式会社 | Ｇｄｐ−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞 |
| JPWO2003085107A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | ゲノムが改変された細胞 |
| CA2481925A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for patients having human fc.gamma.riiia |
| US7691568B2 (en) | 2002-04-09 | 2010-04-06 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-containing medicament |
| AU2003236018A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
| JP4753578B2 (ja) | 2002-06-03 | 2011-08-24 | ジェネンテック， インコーポレイテッド | 合成抗体ファージライブラリー |
| EP3287144A1 (en) | 2002-07-03 | 2018-02-28 | ONO Pharmaceutical Co., Ltd. | Immunopotentiating compositions |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP1572744B1 (en) | 2002-12-16 | 2010-06-09 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| WO2004065416A2 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| WO2005035586A1 (ja) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | 融合蛋白質組成物 |
| EP1705251A4 (en) | 2003-10-09 | 2009-10-28 | Kyowa Hakko Kirin Co Ltd | PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY RNA INHIBITION OF FUNCTION OF $ G (A) 1,6-FUCOSYLTRANSFERASE |
| WO2005040395A1 (en) | 2003-10-22 | 2005-05-06 | Keck Graduate Institute | Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy |
| RS55723B1 (sr) | 2003-11-05 | 2017-07-31 | Roche Glycart Ag | Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom |
| WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
| RU2386638C2 (ru) | 2004-03-31 | 2010-04-20 | Дженентек, Инк. | Гуманизированные анти-тфр-бета-антитела |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| US8318905B2 (en) | 2004-04-23 | 2012-11-27 | Richard Kroczek | Antibodies for depletion of ICOS-positive cells in vivo |
| WO2006004716A2 (en) | 2004-06-29 | 2006-01-12 | The Johns Hopkins University | Amelioration of drug-induced toxicity |
| AU2006207999A1 (en) | 2005-01-27 | 2006-08-03 | Five Prime Therapeutics, Inc. | Leader sequences for directing secretion of polypeptides and methods for production thereof |
| JP2006265155A (ja) | 2005-03-23 | 2006-10-05 | Link Genomics Kk | 癌の免疫療法 |
| SI1907000T2 (sl) | 2005-06-08 | 2020-07-31 | Dana-Farber Cancer Institute | Postopki in sestavki za zdravljenje persistentne HIV infekcije z inhibicijo programiranih celični smrtnih 1 (PD-1) poti |
| US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
| EP1777523A1 (en) * | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| WO2007056441A2 (en) | 2005-11-07 | 2007-05-18 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
| WO2007064919A2 (en) | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| CA2647282A1 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| AU2007249408A1 (en) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| CN101679966B (zh) | 2007-01-24 | 2014-03-12 | 协和发酵麒麟株式会社 | 具有增强的效应子活性的遗传重组抗体组合物 |
| EP2703011A3 (en) | 2007-05-07 | 2014-03-26 | MedImmune, LLC | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| WO2011020024A2 (en) | 2009-08-13 | 2011-02-17 | The Johns Hopkins University | Methods of modulating immune function |
| ES2681214T3 (es) | 2009-09-30 | 2018-09-12 | Memorial Sloan-Kettering Cancer Center | Inmunoterapia de combinación para el tratamiento del cáncer |
| JP5950824B2 (ja) | 2009-12-07 | 2016-07-13 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 抗腫瘍抗体療法を増強するための方法 |
| JP5894538B2 (ja) | 2010-02-04 | 2016-03-30 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 炎症性ヒトＴｈ１７細胞の増殖および機能を決定的に調節するＩＣＯＳ |
| US9410205B2 (en) * | 2010-02-18 | 2016-08-09 | New York University | Methods for predicting survival in metastatic melanoma patients |
| MX2013005759A (es) * | 2010-11-24 | 2013-07-05 | Hoffmann La Roche | Metodos para detectar bajo grado de inflamacion. |
| CA2830442C (en) * | 2011-03-31 | 2019-09-24 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antibodies directed against icos and uses thereof |
| PL2872646T3 (pl) * | 2012-07-12 | 2018-03-30 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Sposoby przewidywania czasu przeżycia i responsywności na leczenie pacjenta cierpiącego na nowotwór lity z sygnaturą przynajmniej 7 genów |
| EP2911669B1 (en) | 2012-10-26 | 2024-04-10 | The University of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
| RU2701378C2 (ru) | 2013-03-15 | 2019-09-26 | Дженентек, Инк. | Биомаркеры и способы лечения связанных с pd-1 и pd-l1 состояний |
| ES2733546T3 (es) | 2013-03-15 | 2019-11-29 | Bristol Myers Squibb Co | Inhibidores de IDO |
| MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| CN114907481A (zh) | 2015-03-23 | 2022-08-16 | 震动疗法股份有限公司 | Icos的抗体 |
| EP3365372A1 (en) | 2015-10-22 | 2018-08-29 | Jounce Therapeutics, Inc. | Gene signatures for determining icos expression |
| WO2018187191A1 (en) | 2017-04-03 | 2018-10-11 | Jounce Therapeutics, Inc | Compositions and methods for the treatment of cancer |
-
2016
- 2016-10-21 EP EP16791734.3A patent/EP3365372A1/en active Pending
- 2016-10-21 CN CN201680060744.XA patent/CN108350505A/zh active Pending
- 2016-10-21 AU AU2016342269A patent/AU2016342269A1/en not_active Abandoned
- 2016-10-21 WO PCT/US2016/058032 patent/WO2017070423A1/en active Application Filing
- 2016-10-21 US US15/767,172 patent/US10968277B2/en active Active
- 2016-10-21 CA CA2998208A patent/CA2998208A1/en not_active Abandoned
- 2016-10-21 KR KR1020187014170A patent/KR20180066236A/ko unknown
- 2016-10-21 TW TW105134182A patent/TW201723190A/zh unknown
- 2016-10-21 JP JP2018520607A patent/JP2018534927A/ja active Pending
-
2018
- 2018-03-15 IL IL258155A patent/IL258155A/en unknown
-
2019
- 2019-01-14 HK HK19100610.9A patent/HK1258249A1/zh unknown
-
2021
- 2021-02-05 US US17/168,544 patent/US20210340256A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW201723190A (zh) | 2017-07-01 |
| KR20180066236A (ko) | 2018-06-18 |
| US20210340256A1 (en) | 2021-11-04 |
| CA2998208A1 (en) | 2017-04-27 |
| WO2017070423A1 (en) | 2017-04-27 |
| US20180371091A1 (en) | 2018-12-27 |
| US10968277B2 (en) | 2021-04-06 |
| JP2018534927A (ja) | 2018-11-29 |
| EP3365372A1 (en) | 2018-08-29 |
| CN108350505A (zh) | 2018-07-31 |
| IL258155A (en) | 2018-05-31 |
| AU2016342269A1 (en) | 2018-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1258249A1 (zh) | 用於測定icos表達的基因標誌 | |
| HK1245918B (zh) | 使用簽名的地址驗證 | |
| GB201512869D0 (en) | Gene signature for minute therapies | |
| PL3125898T3 (pl) | Farmakofor do indukcji trail | |
| IL294381A (en) | pcna inhibitors | |
| IL249254A0 (en) | Gene expression system | |
| PL3183174T3 (pl) | Układ do pipetowania | |
| GB201717445D0 (en) | Method for determining nucleotide sequence | |
| IL257500A (en) | Altered cullin1 gene | |
| GB201517241D0 (en) | DNA modification | |
| GB201402169D0 (en) | Viral inhibitors | |
| PL3053844T3 (pl) | Paleta | |
| IL254638B (en) | A method for determining tactical operations | |
| GB2516709B (en) | An improved trailing or leading zero counter | |
| GB201519564D0 (en) | Detecting chromosome signatures | |
| GB201515250D0 (en) | Detecting chromosome signatures | |
| GB201511082D0 (en) | Detecting chromosome signatures | |
| GB201602053D0 (en) | Detecting chromosome signatures | |
| AU367105S (en) | Tray | |
| AU366650S (en) | Tray | |
| AU366651S (en) | Tray | |
| AU366717S (en) | Tray | |
| AU2015903081A0 (en) | Novel gene expression signature | |
| GB201516680D0 (en) | Assay for methyltrasferase | |
| GB201514833D0 (en) | Quick weigh |